Daprodustat

Daprodustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) being investigated for the treatment of anemia associated with chronic kidney disease (CKD). It works by increasing the production of erythropoietin (EPO), a hormone that stimulates the production of red blood cells. When used in combination with iron, it helps to increase the number of red blood cells in the body and improve oxygen delivery to tissues. Daprodustat is currently in Phase III clinical trials and is not yet approved for use in the US.

Daprodustat is a medication used for the treatment of anemia caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least four months. It is the first and only FDA-approved oral medication for this condition. 

Daprodustat works by mimicking the body's natural response to low oxygen levels. When the body is low on oxygen, it produces an enzyme called hypoxia-inducible factor (HIF). HIF helps the body produce more red blood cells, which carry oxygen throughout the body. Daprodustat inhibits an enzyme that breaks down HIF, which allows HIF levels to rise and stimulate red blood cell production.

Daprodustat is available in tablet form and is taken once daily. The dosage is determined by a doctor based on the patient's individual needs.

Here are some additional things to know about daprodustat:

• Daprodustat is not a substitute for blood transfusions in patients who need them urgently.
• Daprodustat has not been shown to improve quality of life, fatigue, or patient well-being.
• Daprodustat is not currently approved for use in people with CKD who are not on dialysis.

If you are considering taking daprodustat, you should talk to your doctor about the risks and benefits of this medication.